ReviewHaematologica2009
Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.
Review in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels.Human molecular genetics · 2011Pooled it
- Controllable gene delivery via masked adeno-associated viral vectors.Nature materials · 2026Article
- Between scarcity and surfeit: a familial tale of contradictory iron disorders (β -thalassemia and iron-refractory iron deficiency anemia).Annals of hematology · 2026Article
- Single-Position Peptide Clustering for Peptidomics Reveals Novel Disease Biomarkers and Dysregulated Proteolytic Characteristics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Iron, the Essential Micronutrient: A Comprehensive Review of Regulatory Pathways of Iron Metabolism.Nutrients · 2025Review
- Targeting ferroptosis as a therapeutic strategy for hepatotoxicity.Toxicology reports · 2025Review
- Molecular Mechanisms of Iron Metabolism and Overload.Biomedicines · 2025Review
- Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?Journal of nephrology · 2025Review
- Positively charged cytoplasmic residues in corin prevent signal peptidase cleavage and endoplasmic reticulum retention.Communications biology · 2025Article
- Therapeutic targeting of the hepcidin-ferroportin axis and erythropoietic modulators: a narrative review.Frontiers in medicine · 2025Review
- RationalJournal of medicinal chemistry · 2024Article
- The association of TMPRSS6 gene polymorphism with iron status in Egyptian children (a pilot study).BMC pediatrics · 2024Article
- Type II Transmembrane Serine Proteases as Modulators in Adipose Tissue Phenotype and Function.Biomedicines · 2023Review
- Genetics of myocardial interstitial fibrosis in the human heart and association with disease.Nature genetics · 2023Article
- The global prevalence and ethnic heterogeneity of iron-refractory iron deficiency anaemia.Orphanet journal of rare diseases · 2023Article
- Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.Communications biology · 2022Article
- Downregulation of Matriptase Inhibits Porphyromonas gingivalis Lipopolysaccharide-Induced Matrix Metalloproteinase-1 and Proinflammatory Cytokines by Suppressing the TLR4/NF-BioMed research international · 2022Article
- Iron homeostasis and organismal aging.Ageing research reviews · 2021Review
- Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maintaining the body's levels of iron within precise boundaries is essential for normal physiological function. Alterations of these levels below or above the healthy limit lead to a systemic deficiency or overload in iron. The type-two transmembrane serine protease (TTSP), matriptase-2 (also known as TMPRSS6), is attracting significant amounts of interest due to its recently described role in iron homeostasis. The finding of this regulatory role for matriptase-2 was originally derived from the observation that mice deficient in this protease present with anemia due to elevated levels of hepcidin and impaired intestinal iron absorption. Further in vitro analysis has demonstrated that matriptase-2 functions to suppress bone morphogenetic protein stimulation of hepcidin transcription through cell surface proteolytic processing of the bone morphogenetic protein co-receptor hemojuvelin. Consistently, the anemic phenotype of matriptase-2 knockout mice is mirrored in humans with matripase-2 mutations. Currently, 14 patients with iron-refractory iron deficiency anemia (IRIDA) have been reported to harbor various genetic mutations that abrogate matriptase-2 proteolytic activity. In this review, after overviewing the membrane anchored serine proteases, in particular the TTSP family, we summarize the identification and characterization of matriptase-2 and describe its functional relevance in iron metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.